Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | SORD | Q00796 | 8/20 | 0.33 |
| ▸ | JAK2 | O60674 | 4/20 | 0.32 |
| ▸ | JAK1 | P23458 | 4/20 | 0.32 |
| ▸ | TYK2 | P29597 | 4/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25110305 | 1.00 | ACACB (0.39) | ACACBCYP17A1SORDJAK2JAK1 | |
| SCHEMBL24514483 | 0.90 | ACACB (0.40) | ACACBCYP17A1SORDJAK2JAK1 | |
| SCHEMBL25482372 | 0.90 | ACACB (0.40) | ACACBCYP17A1SORDJAK2JAK1 | |
| SCHEMBL22794503 | 0.87 | ACACB (0.42) | ACACBCYP17A1SORDJAK2JAK1 | |
| SCHEMBL25111321 | 0.87 | ACACB (0.42) | ACACBCYP17A1SORDJAK2JAK1 | |
| SCHEMBL24514460 | 0.87 | ACACB (0.34) | ACACB | |
| SCHEMBL22793919 | 0.86 | ACACB (0.36) | ACACBCYP17A1SORDJAK2JAK1 | |
| SCHEMBL25109471 | 0.84 | ACACB (0.38) | ACACBCYP17A1SORDDGAT2HRH4 | |
| SCHEMBL22794665 | 0.84 | ACACB (0.38) | ACACBCYP17A1SORDDGAT2HRH4 | |
| SCHEMBL25109091 | 0.84 | ACACB (0.38) | ACACBCYP17A1SORDDGAT2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | ACACB 3676/4885CYP17A1 4076/4885SORD 3952/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | ACACB 3440/4885CYP17A1 4121/4885SORD 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.